|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
140,990,000 |
Market
Cap: |
73.88(M) |
Last
Volume: |
2,041,307 |
Avg
Vol: |
1,748,484 |
52
Week Range: |
$0.2971 - $1.74 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
6,000,000 |
6,500,000 |
Total Sell Value |
$0 |
$0 |
$3,000,000 |
$5,657,240 |
Total People Sold |
0 |
0 |
1 |
1 |
Total Sell Transactions |
0 |
0 |
1 |
3 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Larson John William |
Director |
|
2014-09-04 |
4 |
OE |
$7.73 |
$77,300 |
D/D |
10,000 |
228,160 |
|
- |
|
Larson John William |
Director |
|
2014-09-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
217,160 |
|
- |
|
Gregory Philip D |
SVP of Research & CSO |
|
2014-09-02 |
4 |
AS |
$13.45 |
$201,798 |
D/D |
(15,000) |
109,347 |
|
- |
|
Gregory Philip D |
SVP of Research & CSO |
|
2014-09-02 |
4 |
OE |
$3.45 |
$84,840 |
D/D |
15,000 |
124,347 |
|
- |
|
Lanphier Edward O Ii |
President & CEO |
|
2014-08-15 |
4 |
AS |
$13.95 |
$348,798 |
D/D |
(25,000) |
295,000 |
|
- |
|
Lanphier Edward O Ii |
President & CEO |
|
2014-08-15 |
4 |
OE |
$4.11 |
$102,750 |
D/D |
25,000 |
320,000 |
|
- |
|
Wolff Henry Ward |
Exec VP & CFO |
|
2014-08-11 |
4 |
AS |
$14.14 |
$141,677 |
D/D |
(10,000) |
218,347 |
|
- |
|
Wolff Henry Ward |
Exec VP & CFO |
|
2014-08-11 |
4 |
OE |
$7.28 |
$58,240 |
D/D |
8,000 |
228,347 |
|
- |
|
Ramasastry Saira |
Director |
|
2014-08-08 |
4 |
AS |
$14.00 |
$140,000 |
D/D |
(10,000) |
0 |
|
- |
|
Ramasastry Saira |
Director |
|
2014-08-08 |
4 |
OE |
$5.03 |
$50,300 |
D/D |
10,000 |
10,000 |
|
- |
|
Ando Dale G |
VP, Therapeutic Dev. & CMO |
|
2014-08-05 |
4 |
AS |
$12.98 |
$194,846 |
D/D |
(15,000) |
96,579 |
|
- |
|
Ando Dale G |
VP, Therapeutic Dev. & CMO |
|
2014-08-05 |
4 |
OE |
$4.11 |
$54,260 |
D/D |
13,202 |
111,579 |
|
- |
|
Larson John William |
Director |
|
2014-08-04 |
4 |
AS |
$12.56 |
$125,578 |
D/D |
(10,000) |
218,160 |
|
- |
|
Larson John William |
Director |
|
2014-08-04 |
4 |
OE |
$4.00 |
$40,000 |
D/D |
10,000 |
228,160 |
|
- |
|
Kolchinsky Peter |
Former 10% Owner |
|
2014-08-01 |
4 |
S |
$12.82 |
$356,100 |
D/D |
(27,770) |
1,829,426 |
|
- |
|
Gregory Philip D |
SVP of Research & CSO |
|
2014-08-01 |
4 |
AS |
$12.54 |
$188,150 |
D/D |
(15,000) |
109,347 |
|
- |
|
Gregory Philip D |
SVP of Research & CSO |
|
2014-08-01 |
4 |
OE |
$3.45 |
$84,840 |
D/D |
15,000 |
124,347 |
|
- |
|
Kolchinsky Peter |
Former 10% Owner |
|
2014-07-30 |
4 |
S |
$12.35 |
$1,361,606 |
D/D |
(109,590) |
1,857,196 |
|
- |
|
Kolchinsky Peter |
Former 10% Owner |
|
2014-07-29 |
4 |
S |
$12.41 |
$17,464 |
D/D |
(1,407) |
1,966,786 |
|
- |
|
Kolchinsky Peter |
Former 10% Owner |
|
2014-07-28 |
4 |
S |
$12.10 |
$727,474 |
D/D |
(60,081) |
1,968,193 |
|
- |
|
Kolchinsky Peter |
Former 10% Owner |
|
2014-07-25 |
4 |
S |
$12.31 |
$583,951 |
D/D |
(47,429) |
2,028,274 |
|
- |
|
Kolchinsky Peter |
Former 10% Owner |
|
2014-07-24 |
4 |
S |
$12.28 |
$1,523,235 |
D/D |
(124,050) |
2,075,703 |
|
- |
|
Lanphier Edward O Ii |
President & CEO |
|
2014-07-18 |
4 |
AS |
$12.16 |
$303,940 |
D/D |
(25,000) |
295,000 |
|
- |
|
Lanphier Edward O Ii |
President & CEO |
|
2014-07-18 |
4 |
OE |
$4.11 |
$102,750 |
D/D |
25,000 |
320,000 |
|
- |
|
Kolchinsky Peter |
Former 10% Owner |
|
2014-07-17 |
4 |
B |
$12.26 |
$456,211 |
D/D |
37,215 |
2,199,753 |
2.44 |
- |
|
539 Records found
|
|
Page 20 of 22 |
|
|